Addressing multiple overdoses: Opportunities for prevention and innovation.
Addressing multiple overdoses: Opportunities for prevention and innovation.
复制标题
解决多种药物过量:预防和创新的机会。
DOI:
10.1016/j.drugpo.2021.103382
复制
发表时间:
2021-10
期刊:
影响因子:
--
通讯作者:
Hadland SE
中科院分区:
文献类型:
--
作者:
Bagley SM;Hadland SE
Fatal and nonfatal drug overdose (NFOD) is common and increasing globally (Fact Sheet: Opioid Overdose, 2020). Preliminary data from the United States show that against the backdrop of the global Covid pandemic, there is likely to be an even greater surge in the time to come (Ahmad et al., 2021; Friedman & Akre, 2021). Globally, more than 70% of fatal drug overdose deaths involve opioids. One of the most significant risk factors for fatal overdose is prior nonfatal opioid overdose (Krawczyk et al., 2020; Olfson et al., 2018). Nonfatal opioid overdose provides an opportunity for identification and interventions such as naloxone and medications for opioid use disorder (buprenorphine and methadone) to mitigate future risk and provide protection against both opioid-related and all-cause mortality (Larochelle et al., 2018; Walley et al., 2013).In this issue of International Journal of Drug Policy, Geddes et al. examined the prevalence of and risk factors for multiple NFOD among individuals who participated in the 2019 Australian Needle and Syringe Program Survey. Eligible participants reported a NFOD in the prior 12 months and injection of an opioid at the most recent NFOD. In a cohort of 222 individuals, 59% were male, 39% were under 39 years-old, 23% were Indigenous, 73% had used heroin at the last NFOD, and 48% had multiple NFOD (median 3, IQR 1–6). In adjusted analyses, the authors found that public injecting and benzodiazepine use in the 12 hours prior to NFOD were risk factors for multiple NFOD compared to individuals with a single nonfatal opioid overdose in the prior 12 months.
登录
查看更多内容
影响因子:
6.2
作者:
Krawczyk, Noa;Eisenberg, Matthew;Saloner, Brendan
通讯作者:
Saloner, Brendan
影响因子:
12.7
作者:
Friedman, Joseph;Akre, Samir
通讯作者:
Akre, Samir
影响因子:
4.4
作者:
Peiper, Nicholas C.;Clarke, Sarah Duhart;Zibbell, Jon E.
通讯作者:
Zibbell, Jon E.
影响因子:
168.9
作者:
Marshall, Brandon D. L.;Milloy, M-J;Kerr, Thomas
通讯作者:
Kerr, Thomas
DOI:
10.1136/bmj.f174
发表时间:
2013-01-30
期刊:
BMJ (Clinical research ed.)
影响因子:
--
作者:
Walley AY;Xuan Z;Hackman HH;Quinn E;Doe-Simkins M;Sorensen-Alawad A;Ruiz S;Ozonoff A
通讯作者:
Ozonoff A